Last reviewed · How we verify
TT301
At a glance
| Generic name | TT301 |
|---|---|
| Also known as | TT301 iv |
| Sponsor | OPKO Health, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) (PHASE2)
- A MAD Study of TT301/MW189 in Healthy Volunteers (PHASE1)
- Effects of TT301 on Cytokine Levels Post Endotoxin Challenge (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TT301 CI brief — competitive landscape report
- TT301 updates RSS · CI watch RSS
- OPKO Health, Inc. portfolio CI